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Abstract Previously, we showed that CD206-targeted lipo-
somal delivery of co-encapsulated immunodominant myelin
basic protein (MBP) sequences MBP46–62, MBP124–139 and
MBP147–170 (Xemys) suppressed experimental autoimmune
encephalomyelitis in dark Agouti rats. The objective of this
study was to assess the safety of Xemys in the treatment of
patients with relapsing-remitting multiple sclerosis (MS) and
secondary progressive MS, who failed to achieve a sustained
response to first-line disease-modifying therapies. In this
phase I, open-label, dose-escalating, proof-of-concept study,
20 patients with relapsing-remitting or secondary progressive
MS received weekly subcutaneously injections with ascend-
ing doses of Xemys up to a total dose of 2.675 mg. Clinical
examinations, including Expanded Disability Status Scale
score, magnetic resonance imaging results, and serum cyto-
kine concentrations, were assessed before the first injection
and for up to 17 weeks after the final injection. Xemys was
safe and well tolerated when administered for 6 weeks to a
maximum single dose of 900 μg. Expanded Disability Status
Scale scores and numbers of T2-weighted and new
gadolinium-enhancing lesions on magnetic resonance imag-
ing were statistically unchanged at study exit compared with
baseline; nonetheless, the increase of number of active
gadolinium-enhancing lesions on weeks 7 and 10 in compar-
ison with baseline was statistically significant. During treat-
ment, the serum concentrations of the cytokines monocyte
chemoattractant protein-1, macrophage inflammatory pro-
tein-1β, and interleukin-7 decreased, whereas the level of tu-
mor necrosis factor-α increased. These results provide evi-
dence for the further development of Xemys as an antigen-
specific, disease-modifying therapy for patients with MS.
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Introduction
Multiple sclerosis (MS) is a chronic neurodegenerative dis-
ease with an evident autoimmune background resulting in
inflammatory demyelination and axonal and neuronal injury
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[1]. MS, which was first described in 1868 [2], is one of the
most common diseases of the nervous system. It affects peo-
ple aged 20–40 years worldwide, although it has higher oc-
currence in women than in men and in those residing in north-
ern than in southern latitudes. Despite its long history and the
finding that immune cells rather than exogenous pathogens
are responsible for MS development [3], the etiology of MS
remains unclear.
Several treatment strategies for MS have been found to be
moderately successful [4]. For example, the β-interferons and
glatiramer acetate (GA) are disease-modifying therapies with
an established history of efficacy and safety in clinical practice
[5–7]. In addition, monoclonal antibodies binding to specific
ligands have been found effective; these include natalizumab,
which binds to α4 integrins [8]; daclizumab, which binds to
CD25 [9]; and alemtuzumab, which binds to CD52 [10].
Natalizumab and alemtuzumab have been approved by the
US Food and Drug Administration for the treatment of refrac-
tory MS, while daclizumab approval is very likely in the near
future. Despite their effectiveness, however, these agents have
been associated with serious adverse events (SAEs), signifi-
cantly restricting their further application [4]. Novel, conve-
nient oral therapies, including fingolimod [11], teriflunomide
[12], and dimethyl fumarate [13], have shown efficacy and
tolerability and have been approved for the treatment of pa-
tients with MS.
However, some patients remain refractory to these
agents. This may be due to as yet unknown triggers of
MS, together with high heterogeneity of this disease.
Therefore, searching for novel, antigen-specific immuno-
therapeutic treatment options for MS is highly feasible
[14]. For example, myelin basic protein (MBP), the struc-
tural component of the myelin membrane, is thought to be
a primary target of the immune system during MS devel-
opment [15]. Attempts have been made to induce toler-
ance toward MBP and its structural constituents [16–20],
including MBP pulsing of dendritic cells [21]. In our pre-
vious studies using a newly designed MBP epitope li-
brary, we determined that MBP peptides 46–62, 124–
139 and 147–170, but not 83-99, were the most
immunodominant in terms of autoantibody responses in
patients with MS when compared with healthy individuals
and patients with other neurological diseases lacking an
autoimmune background [22, 23]. Nasal administration of
these MBP peptides suppressed protracted relapsing ex-
perimental allergic encephalomyelitis (EAE) in dark
Agouti rats [24]. Further, selected immunodominant
MBP peptides encapsulated into mannosylated liposomes
were reported effective in the treatment of EAE [25].
Mannosylation of these liposomes was found critical for
their therapeutic efficiency, as animals that received
nonmannosylated peptide-loaded liposomes were unable
to recover from the first EAE attack. The most reasonable
explanation that was confirmed experimentally suggests
that mannosylation of liposomes significantly enhances
their uptake by dendritic cells via the CD206 receptor
[25], resulting in immune system tolerance towards mye-
lin antigens. The synergistic liposome-mediated effects of
coencapsulated MBP peptides reduced overall disease
course, resulting in moderate severity of attacks and faster
recovery from exacerbations [25]. Preclinical studies
showed that administration of the designed formulation,
at doses largely exceeding those proposed for humans, did
not induce significant AEs in animals. The aim of the
present study was to explore the AE profile and tolerabil-
ity of encapsulated MBP peptides in a cohort of patients
with MS. Secondary outcomes were to evaluate the effects
of these peptides on the clinical course of MS.
Methods
Study Design
This was a phase I, multicenter, open-label, dose-escalating
safety, and proof-of-concept study of the oligopeptides
MBP46–62, MBP 124–139, and MBP 147–170 coencapsulated in
CD206-targeted small monolammelar liposomes (Xemys;
Pharmsynthez, St. Petersburg, Russia [25]) in patients with
relapsing-remitting (RRMS) or secondary progressive MS
with superimposed relapses (SPMS) who failed to achieve
sustained responses to first-line disease-modifying therapies
(FASEMS). The FASEMS clinical trial schedule is summa-
rized in Fig. 1A. Patients received 6 weekly subcutaneous
injections, on the same day each week, of Xemys at doses
ascending from 50 μg to 900 μg. After the last injection,
patients were followed up for 12 weeks.
The primary endpoint was the safety of Xemys, as deter-
mined by the frequency and severity of adverse events (AEs)
and SAEs. To ensure patient safety, the patients were divided
into 2 cohorts. Dose-limiting toxicities (DLT) and dose adjust-
ments were assessed in the first cohort; doses in the second
cohort were limited to the highest first-cohort dose not asso-
ciated with DLT. If there were no DLTs in the first cohort, the
dosing regimen would remain unaltered in the second cohort.
Secondary clinical endpoints included the number of
relapses during the study period and Expanded
Disability Status Scale (EDSS) score at the end of the
trial. Secondary magnetic resonance imaging (MRI) end-
points included the number of gadolinium-enhancing T1
lesions and the total number of lesions in T2 and fluid-
attenuated inversion recovery (FLAIR) sequences.
Laboratory endpoints included the concentrations of pro-
and anti-inflammatory cytokines. The study was approved
by the Russian Ministry of Health, the Central Ethics
Commission, and all local ethic committees, and was
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20 patients passed
cohort 01: n=10
cohort 02:  n=10
20 patients given increasing sc injections of Myeloxen
once weekly, 6 injections, 2.675 mg totally
cohort 01: n=10
cohort 02:  n=10
18 patients completed
cohort 01: n=9
cohort 02:  n=9
2 patients withdrawn
cohort 01: n=1
cohort 02:  n=1
Inclusion criteria
– age 18-55
– diagnosed MS according McDonald criteria 2005
– unsuccessful treatment by immuno-modulators/
   -suppressants including GA and β-interferons
– stabilization >30 d. at the time of screening
β-interferons >30 d. at the time of visit 1
Reasons for exclusion
– primary-progressive MS
– clinically relevant infection or surgical intervention <30 d.
   at the time of screening visit
– body-weight index >40 kg/m2
– hypersensitivity towards components of Myeloxen or GA
– oncology
– previous therapy using cladribine, alemtuzumab, rituximab,
   natalizumab, daclizumab, IVIg
– previous therapy in less than 6 mo. using cyclophosphamide,
   mitoxantrone, ciclosporin, mycophenolate mofetil,
   azathioprine, methotrexate, plasmapheresis
– administration of glucocorticoids in <1 mo. in a daily dosage 


















































Fig. 1 (A) Protocol schedule.
Timeline showing major clinical
and investigational elements of
the study. (B) Subject allocation.
Summary of screening outcome,
treatment allocation, and study
completion. Rx = treatment;
EDSS = Expanded Disability
Status Scale; MRI = magnetic
resonance imaging; MS =
multiple sclerosis; GA =
glatiramer acetate; IVIg =
intravenous immunoglobulin
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conducted in full compliance with the Declaration of
Helsinki, International Conference on Harmonisation’s
Good Clinical Practice, and appropriate local legislation.
Subjects
Subjects were screened 2 weeks before enrollment into the
treatment phase of the study (Fig. 1B). The trial involved
patients with RRMS or SPMS with superimposed relapses,
defined as previously described [26]. Subjects were included
if they were aged 18–55 years, had an EDSS from 3 to 5.5 and
a ≥ 1.0 increase during the previous 6 months, and had > 1
relapse during the previous year [27]. Subjects also had to be
stable for > 30 days at the time of screening and to have not
received treatment with GA or β-interferons for > 30 days at
the time of visit 1. Female subjects had to have negative preg-
nancy tests.
Subjects were excluded if they had primary progressive
MS; clinically relevant infection or surgical intervention <
30 days before the screening visit; contraindications to MRI
scanning, including hypersensitivity toward gadolinium; a
body mass index > 40 kg/m2; or hypersensitivity toward com-
ponents of a test i tem (egg phosphatidylcholine,
monomannosyl dioleyl glycerol, α-tocopherol, or lactose) or
GA. Subjects were also excluded if they had liver decompen-
sation; heart diseases; tuberculosis in anamnesis; significantly
abnormal hematological or biochemical parameters; oncolog-
ical diseases; previous therapy with cladribine, alemtuzumab,
rituximab, natalizumab, daclizumab, or intravenous immuno-
globulin; treatment with any disease-modifying therapy dur-
ing the previous 6 months, including cyclophosphamide,
mitoxantrone, ciclosporin, mycophenolate mofetil, azathio-
prine, methotrexate, or plasmapheresis; or had been adminis-
tered glucocorticoids within the last month at a daily dosage
equivalent to > 60 mg of prednisolone.
The study was authorized by the Russian Public Health
Ministry #930 (FASEMS-01/01) issued on 28 April 2012.
All patients provided written informed consent at enrollment
after discussion of the study with investigators including pos-
sible alternative treatment options. Details of full medical his-
tory and MS pathogenesis were collected.
Procedures
Lyophilized Xemys consists of equimolar amounts of
lyophilized, chemically synthesized MBP peptides
46–62 (GGDRGAPKRGSGKDSHH) , 124–139
( G F G Y G G R A S D Y K S A H K ) , a n d 1 4 7 – 1 7 0
(QGTLSKIFKLGGRDSRSGSPMARR) (total 0.45 mg) en-
capsulated in small unilamellar liposomes prepared from egg
phosphatidylcholine and monomannosyl dioleyl glycerol with
the addition of α-tocopherol and lactose (total 125 mg). Each
dose was rehydrated in 1.0 ml sterile water immediately
before administration. The starting dose, consisting of 0.05-
mg peptides, was chosen as the minimum to detect any unpre-
dictable AEs without significant risk to the patients. Patients
received weekly subcutaneous injections of Xemys at escalat-
ing doses over 6 weeks of 50 μg, 150 μg, 225 μg, 450 μg, 900
μg, and 900 μg, yielding a total dose of 2.675 mg.
Patients were followed-up 1, 4, and 12 weeks after
administration of the last dose, corresponding to study
weeks 7, 10, and 18, respectively. AEs were monitored
by 12-lead electrocardiography, hematology, and labora-
tory tests, and scored according to the Common
Terminology Criteria for Adverse Events version 4.0.
Any SAEs deemed “certainly” or “likely” due to the
study drug were considered DLTs, with the next lowest
dose level considered the maximum tolerated dose.
Patients also underwent complete neurological examina-
tions during each study visit. An MS exacerbation was
defined as a new worsening of neurological function last-






Age (years)* 37.6 ± 9.9 (24–53)
Sex† 9–11 (45%)
Weight (kg)* 69.7 ± 15.8 (44–105.5)
* Average ± SD (range)
† Female – male (female %)
Table 2 Multiple sclerosis (MS) anamnesis
Anamnestic criterion Variable (n = 20)
MS type
Relapsing-remitting 16 (80%)








First signs of MS* 10.4 ± 6.8 (0.9–25.8)
MS diagnosis* 5.0 ± 3.6 (0.6–13.3)
MS exacerbations during the last:†
1 year 2.0 (1–3)
2 years 3.0 (1–6)
Data are presented as n (%) unless otherwise indicated
*Average ± SD, min–max (years)
†Median (min–max)
EDSS = Expanded Disability Status Scale
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EDSS was determined at baseline (week 2) and at all
follow-up visits. Patients underwent MRI scans, including
T1-weighted axial scans with and without gadolinium, pro-
ton density axial, T2-weighted axial, T2-weighted sagittal,
and FLAIR sequence axial images, at baseline and at
follow-up visits at weeks 7, 10, and 18. Scans were per-
formed with Philips, Amsterdam, Netherlands Integra
1.5T, Magnetom Avanto 1.5T, and GE Medical Systems,
Milwaukee, WI, USA Signa 1.5T scanners.
Serum samples for cytokine analysis were collected at base-
line and during all follow-up visits. The profiles of 17 cyto-
kines and chemokines were determined using a multiplexed
fluorescent magnetic bead-based immunoassay (Bio-Rad
Laboratories, Berkeley, CA, USA), according to the manufac-
turer’s instructions. These 17 cytokines and chemokines in-
cluded interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8,
IL-10, IL-12 (p70), IL-13, IL-17A, granulocyte colony-
stimulating factor, granulocyte macrophage colony-
stimulating factor, interferon-γ, monocyte chemoattractant
protein-1 (MCP-1/CCL2), macrophage inflammatory protein
(MIP-1b/CCL4), and tumor necrosis factor (TNF)-α.
Statistical Analysis
Demographic data, baseline characteristics, safety and tolera-
bility variables, and other parameters under investigation were
calculated using descriptive statistics. Safety and tolerability
were assessed in patients who received at least 1 dose of the
studied substance. AEs were grouped by dose and classified
by MedDRA system organ classes and preferred terms, with
severity classified by Common Terminology Criteria for
Adverse Events version 4.0. Secondary endpoints were ana-
lyzed in patients who received at least 1 dose of the studied
substance and underwent at least 1 assessment. The normality
of the data was determined using Kolmogorov–Smirnov tests;
all datasets were non-normally distributed. Changes from
baseline in the number of MRI lesions were assessed by anal-
ysis of variance. Mann–Whitney t tests were used to compare
between-group variables and the Wilcoxon signed rank test
for within-group variables. All tests were two sided, and p-
values < 0.05 were considered significant. All statistical anal-
yses were performed with SPSS (IBM, Armonk, NY, USA)
and GraphPad Prism 6.0 (GraphPad Inc., La Jolla, CA, USA).
Results
Between April 2013 and July 2014, 20 patients with RRMS or
SPMS matching all criteria were directly recruited into the
trial at 4 clinical centers in the Russian Federation. Baseline
characteristics of patients with MS are listed in Table 1.
Table 4 Adverse events by
MedDRA preferred term and by
Common Terminology Criteria
for Adverse Events (CTCAE)
severity grades
System organ class/preferred term Grade by CTCAE 4.0*
1 grade (mild) 2 grade (moderate)
Total 6 (30%)/13 2 (10%)/3
Gastrointestinal 0 2 (10%)/2
Pain in upper abdomen 0 1 (5%)/1
Diarrhea 0 1 (5%)/1
General disorder and administration site conditions 4 (20%)/10 0
Weakness 1 (5%)/2 0
Injection site reaction 4 (20%)/8 0
Infection and infestation 2 (10%)/2 0
Rhinitis 2 (10%)/2 0
Nervous system disorders 1 (5%)/1 0
Spasm of muscles of lower extremities 1 (5%)/1 0
Vascular disorders 0 1 (5%)/1
Essential hypertension 0 1 (5%)/1
*Data are presented as n (%)/c, where n = number of subjects, % = part of subjects with c = number of adverse
events
Table 3 Overview of adverse events (AEs)
Total (n = 20)* 8 (40%)/16
Serious AEs 0
AE, drug related 5 (25%)/ 11
AE, led to drug interruption 0
AE, required therapy 2 (10%)/ 2
Suspected unexpected serious adverse reactions 0
Deaths 0
*Data are presented as n (%)/c, where n = number of subjects, % = part of
subjects with c = number of AEs
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Inclusion and exclusion criteria, as well as the numbers of
patients screened and enrolled in the study, are summarized
in Fig. 1B. Of the 20 patients, 16 (80%) had RRMS and 4
(20%) had SPMS with relapses. At baseline, 3 (15%) patients
had mild disability according to EDSS score (3.0), and 17
(85%) had moderate disability (3.5–5.5) (Table 2). Nineteen
patients received all 6 weekly doses of encapsulated MBP
peptides (total 2.675 mg) (Fig. 1A). One patient who received
all 6 doses of Xemys discontinued from the study after treat-
ment period at week 6 (his own decision); 1 patient received
only the first 50-μg dose and chose to discontinue after 1 week
(his own decision).
As no patient experienced a DLT during treatment, an
maximum-tolerated dose was not reached, making it likely
to be > 900 μg per week. Eight patients (40%) experienced
16 AEs (Table 3), with 11 events in 5 (25%) patients
regarded as related to the Xemys injections. No SAEs,
serious drug reactions, or deaths occurred during the study.
Of the 16 AEs, 13, in 6 (30%) patients, were regarded as
grade 1, and 3 AEs, in 2 (10%) patients, were regarded as
grade 2 (Table 4). No AE met the seriousness criteria of
International Conference on Harmonisation E6. All drug-
related AEs were grade 1 in severity, except for diarrhea,
which was grade 2 (Table 5). All AEs resolved without
treatment and did not require interruption or discontinua-
tion of the investigational drug.
The most common AE was local reaction at the site
of injection, which was observed 8 times in 4 (20%)
Table 6 Magnetic resonance
imaging (MRI) lesions by visits Visit MRI regime n MRI Lesions
Mean* Median Min-max Q 25% Q 75%
Baseline T1 19 0.3 ± 0.6 0.0 0–2 0.0 0.0
T2 45.2 ± 20.0 44.0 18–97 23.0 60.0
FLAIR 46.9 ± 20.4 44.0 21–96 24.0 62.0
Week 7 T1 18 1.3 ± 1.9 1.0 0–6 0.0 2.0
T2 47.7 ± 21.7 47.0 18–101 25.0 62.0
FLAIR 49.2 ± 22.1 47.0 23–100 25.0 67.0
Week 10 T1 19 1.3 ± 2.0 0.0 0–6 0.0 2.0
T2 47.5 ± 22.0 44.0 18–104 28.0 60.0
FLAIR 48.5 ± 21.6 44.0 23–103 28.0 62.0
Week 18 T1 18 1.3 ± 2.8 0.0 0–11 0.0 1.0
T2 48.2 ± 22.2 45.0 19–105 31.0 60.0
FLAIR 49.6 ± 22.0 46.0 24–104 31.0 62.0
*Average ± SD
FLAIR = fluid-attenuated inversion recovery
Table 5 Adverse events by
MedDRA preferred term and
relationship to study drug
System organ class/preferred term Relationship (n = 20)*
Not related Possible Likely
Total 3 (15%)/5 1(5%)/1 5 (25%)/10
Gastrointestinal 1 (5%)/1 0 1 (5%)/1
Pain in upper abdomen 1 (5%)/1 0 0
Diarrhea 0 0 1 (5%)/1
General disorder and administration site conditions 0 1(5%)/1 4 (20%)/9
Weakness 0 1(5%)/1 1 (5%)/1
Injection site reaction 0 0 4 (20%)/8
Infection and infestation 2 (10%)/2 0 0
Rhinitis 2 (10%)/2 0 0
Nervous system disorders 1 (5%)/1 0 0
Spasm of muscles of lower extremities 1 (5%)/1 0 0
Vascular disorders 1 (5%)/1 0 0
Essential hypertension 1 (5%)/1 0 0
*Data presented as n (%)/c, where n = number of subjects, % = part of subjects with c = number of adverse events
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patients. Most injection site reactions occurred at admin-
istration of submaximal (0.45 mg) and maximal (0.9
mg) doses of Xemys; all resolved within 24 h without
treatment. Rhinitis occurred twice in 2 patients (10%)
each and general weakness twice in 1 (5%) patient.
Other AEs occurred only once in single patients.
Xemys did not have any effect on laboratory safety
tests, vital signs (body temperature, heart rate, respira-
tion rate and blood pressure), results of physical exam-
ination, or electrocardiography parameters (heart rate,
PR interval, QRS duration, and QT interval). In general,
the administered doses of Xemys were considered safe
and tolerable.
Patients underwent MRI scans at baseline (week –2) and
after treatment, at weeks 7, 10, and 18, using T1-weighted
(with and without contrast), T2, and FLAIR regimens.
Nineteen patients were evaluated at baseline and week 10,
and 18 patients at weeks 7 and 18 (Table 6, Fig. 2A). At
baseline, 16 (84%) patients had no active gadolinium-
enhancing lesions. By week 7, however, active lesions were
detected in 10 (56%) patients, and at last follow-up, 8 (33.7%)
patients had active lesions. Although a trend towards an in-
creasing number of gadolinium-enhancing lesions was detect-
ed, per subject-specific analysis of MRI results at time of
study exit showed that 83% of patients had 0±1 new lesions,
with only 3 patients (17%) having > 1 new lesion (Fig. 2B). To
assess changes in the number of MRI lesions in comparison
with baseline, ANOVA was performed, with the dependent
variable being the rank of the number of MRI lesions
(Table 7). All datasets were non-normally distributed.








































































































































Fig. 2 (A) Cumulative change in mean number of new gadolinium-
enhancing and T2-weighted (w) lesions. (B) Change in number of
gadolinium (Gd)-enhancing lesions at study exit (18 weeks). (C)
Concentrations of serum cytokines at screening (–2 weeks), 7, 10, and
18 weeks. The bold lines represent the medians and the boxes represent
interquartile ranges. Bars represent 95% confidence intervals. Statistically
significant differences (p < 0.05) are indicated. (D) Vector plots showing
changes in serum tumor necrosis factor (TNF)-α concentrations and
numbers of gadolinium-enhancing lesions in studied patients. Positive
and negative correlations between TNF-α level and number of
gadolinium-enhancing lesions are shown in red and blue, respectively.
Numbers represent patient identifications. Aver = average; Q = quartile;
min = minimal value; max = maximal value; MIP = macrophage
inflammatory protein; MCP = monocyte chemoattractant protein; IL =
interleukin
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Relative to baseline, the increases in the number of active
gadolinium-enhancing lesions were statistically significant at
weeks 7 and 10 (F = 3.015, p = 0.038), but not at week 18 (p >
0.05). At last follow-up, 16/19 (85%) patients were relapse-
free, and EDSS worsened in 21% and improved in 10% of
patients. The disease histories, and clinical andMRI outcomes
of individual patients are summarized in Table 8.
To analyze the immunological consequences of
Xemys administration, the concentrations of 17 serum
cytokines and chemokines were analyzed at follow-up
time points (Fig. 2C). Compared with baseline, MCP-
1, MIP-1β, and IL-7 concentrations were significantly
lower and TNF-α was significantly higher at study exit
(week 18).
Table 8 Patients' history, magnetic resonance imaging, and clinical outcome measures at study exit














7001 RRMS 7.8 3 IFN-β 0 0 0 N
7002 RRMS 9.9 2 IFN-β 0 0 –0.5 N
7004 RRMS 3.9 2 IFN-β 1 2 –1 N
7005 RRMS 1.5 2 IFN-β 3 2 0 N
7006 RRMS 1.5 1 IFN-β 0 2 0.5 Y
7007 RRMS 6.5 2 GA -1 10 1 Y
7008 SPMS 0.6 1 IFN-β 0 0 0 Na
5001 RRMS 6.0 1 IFN-β 10 0 0 N
5002 SPMS 9.9 2 IFN-β 0 0 0 N
5003 SPMS 4.3 1 IFN-β 0 0 0 N
4001 RRMS 1.4 1 GA 0 13 0 N
4002 SPMS 9.4 2 IFN-β 0 9 0 N
4003 RRMS 2.9 1 IFN-β 0 0 0 N
4004 RRMS 4.7 1 IFN-β 0 2 0 N
4005 RRMS 7.2 3 IFN-β 0 1 0 N
4006 RRMS 0.7 2 IFN-β 0 1 0.5 N
4007 RRMS 2.6 2 IFN-β 0 0 0 N
2001 RRMS 13.3 2 GA 1 1 0.5 N
2002 RRMS 3.2 3 GA/IFN-β 4 8 0 Y
*GA – glatiramer acetate
a The last visit is Day 64, Day 120 is missing
EDSS = Expanded Disability Status Scale; RRMS = relapsing-remitting multiple sclerosis; IFN = interferon; GA = glatiramer acetate; SPMS =
secondary progressive multiple sclerosis




95% CI Pared comparison F‡ p‡
Difference of means*,† p 95% CI
Baseline 2.0 ± 0.2 (1.5-
2.4)
3.015 0.038
Week 7 2.8 ± 0.2 (2.4-
3.3)
–0.9 ± 0.3 0.006 (–1.50 to –0.27)
Week 10 2.6 ± 0.2 (2.2-
3.0)
–0.7 ± 0.3 0.035 (–1.25 to –0.05)
Week 18 2.4± 0.2 (2.0-
2.9)
–0.5 ± 0.3 0.115 (–1.11 to 0.12)
* Data are presented ± SE
†Difference of means between baseline and weeks 7, 10, and 18
‡ For “visit” factor assessment
CI = confidence interval
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Discussion
This study showed that subcutaneous administration of
Xemys was safe and well tolerated in patients with MS who
had previously failed to achieve sustained disease control fol-
lowing treatment with GA or β-interferons. The AEs related
to Xemys were of mild or moderate severity and occurred
mainly after treatment with submaximal and maximal doses
of Xemys. These AEs were self-limiting, required no concom-
itant medication, and did not cause abnormalities in blood
tests or other safety measures. Taken together, these findings
showed that once-weekly Xemys has a relatively good safety
profile.
Patients included in the FASEMS trial have experi-
enced significant disease activity, despite previous first-
line disease-modifying treatment. Importantly, 12 weeks
after the end of Xemys administration, 7 patients (37%)
showed no evidence of disease activity, and 16 (85%)
were relapse-free. Although EDSS levels and the num-
bers of T2-weighted lesions and new gadolinium-
enhancing lesions on MRI in comparison with baseline
were statistically unchanged at study exit, a statistically
significant increase in the number of active gadolinium-
enhancing lesions on weeks 7 and 10 in comparison with
baseline was detected. Here we emphasize that all pa-
tients included in this study had experienced > 1 relapse
during the previous year, had progressing EDSS, and at
the same time had disease stabilization for at least 30
days before screening. Therefore, the number of
contrast-enhancing lesions may have had a natural ten-
dency to increase during the course of the study. The
lack of a placebo group reasoned by approved study
design did not allow comparative monitoring of disease
progression, including the number of gadolinium-
enhancing lesions, in the absence of therapeutic interven-
tion. Finally, the statistically significant increase in the
number of gadolinium-enhancing lesions was assessed
only in a small group of patients who experienced re-
lapse. Thus, the appearance of these lesions was not
likely associated with treatment, although this possibility
cannot be completely excluded.
Our preliminary data also suggest that there were no
consistent trends in serum cytokine profiles. However,
the concentrations of MCP-1, MIP-1β, and IL-7 were sig-
nificantly lower after treatment that at baseline.
Immunologically, Xemys administration is thought to re-
strict monocyte cell trafficking. Although a classical pro-
inflammatory cytokine TNF-α has been previously shown
to have potent beneficial effects in autoimmune neurode-
generation [28], reported herein increase in concentration
of serum TNF-α in treated patients with MS had likely no
protective input. Despite the absence of a distinct link be-
tween changes of the number of gadolinium-enhancing
lesions and dynamic of serum level of TNF-α, a rather
positive correlation was observed (Fig. 2D).
In conclusion, this phase I trial showed that once-weekly
subcutaneous Xemys for 6 weeks, at a cumulative dose of
2.675 mg, was safe and well tolerated by patients with
RRMS and SPMS. Preclinical and clinical data warrant the
further development of Xemys as an antigen-specific disease-
modifying therapy for patients with MS.
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